Market Overview

Bank Of America Initiates United Therapeutics With Bearing Rating, Cites Unclear Growth Outlook

Share:
Bank Of America Initiates United Therapeutics With Bearing Rating, Cites Unclear Growth Outlook

United Therapeutics Corporation (NASDAQ: UTHR) may face stiffening competition from generic entrants, which could meaningfully increase pricing pressure and shrink its market share, according to Bank of America Merrill Lynch

The UTHR Analyst

BofA's Geoff Meacham initiated coverage of United Therapeutics with an Underperform rating and a price target of $80.

The Thesis

United Therapeutics’ efforts to enhance its portfolio have gone through a number of setbacks, Meacham said in the initiation note.

He expects the company’s revenue and earnings to decline between 2020 through 2022. This would result in lower free cash flow generation, which could negatively impact its capital deployment activities.

United Therapeutics has been investing in its core Pulmonary Arterial Hypertension (PAH) pipeline but progress has been limited, Meacham noted. He added that there is risk of further competition in this space, with several disruptive new formulations and novel MOAs (Mechanisms of Action) advancing in development.

On the other hand, the phase III BEAT (Beraprost 314d Added-on to Tyvaso) of prostacyclin analog esuberaprost had failed in the second quarter, while efforts the phase III SOUTHPAW of Orenitram has been halted, the analyst mentioned.

Given the lack of visibility into United Therapeutics’ longer-term growth drivers and the generic headwinds, “we remain very cautious on shares,” Meacham wrote.

United Therapeutics Price Action

Shares of United Therapeutics had declined more than 3% to $88.54 at the time of publishing on Tuesday.

Latest Ratings for UTHR

DateFirmActionFromTo
Aug 2019UpgradesNeutralBuy
Aug 2019UpgradesUnderperformHold
Jul 2019UpgradesNeutralOutperform

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: Bank of America Geoff MeachamAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (UTHR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AMRXRaymond JamesDowngrades
MDStifelUpgrades33.0
CATStandpoint ResearchDowngrades
LULUPiperJaffrayMaintains245.0
LULUWells FargoMaintains260.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Option Traders Betting Against Bank Of America Following Trump Tariff Comments

Esports Hits The Big Time: Top 'Counter-Strike' Team Plans Danish IPO